Premium
Characteristics and prognosis of primary thyroid non‐Hodgkin's lymphoma in Chinese patients
Author(s) -
Sun TuanQi,
Zhu XiaoLi,
Wang ZhuoYing,
Wang ChaoFu,
Zhou XiaoYan,
Ji QingHai,
Wu Yi
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21543
Subject(s) - medicine , radiation therapy , univariate analysis , chemotherapy , multivariate analysis , thyroid , stage (stratigraphy) , thyroid lymphoma , lymphoma , international prognostic index , surgery , oncology , diffuse large b cell lymphoma , paleontology , thyroiditis , biology
Background and Objectives There exists no universally accepted treatment for primary thyroid non‐Hodgkin's lymphoma (TNHL) due to the rarity of this entity. The aim of this study is to assess the role of surgery and to explore prognostic factors in Chinese TNHL patients. Methods Patient presentations, pathologies, surgical interventions, multidisciplinary treatment, prognostic factors and the value of fine needle aspiration were analyzed. Results Between 1991 and 2007, 40 patients of TNHL were diagnosed. Thirty‐eight patients underwent an initial surgical procedure. Further treatments consisted of radiotherapy or chemotherapy alone, and the majority of patients were treated with combined chemo‐radiation. After a median follow‐up of 95 months, the 5‐year overall survival (OS) and relapse‐free survival (RFS) was 82% and 74%, respectively. Survival curves showed no significant difference between therapeutic operations when compared with diagnostic operations. A univariate analysis showed both International Prognostic Index (IPI) and staging significantly influenced OS and RFS. In multivariate analysis, IPI was found to be the only prognostic factor. Conclusions Combined chemotherapy and radiotherapy may offer better outcome without the need for extensive resection, and surgery should be reserved to providing tissue for diagnosis. The patients with low‐intermediate risk (IPI = 2) or stage IIE need be treated more aggressively. J. Surg. Oncol. 2010; 101:545–550. © 2010 Wiley‐Liss, Inc.